Type II EAC

Question 1

5y cause specific OS for s.I/II g3 EAC, UPSC and clear cell ca: Mayo data on 119, 211 and 40 pts, treated between 1999-2008

Answer 1

Not much difference: ~ LVSI only

g3 EAC: 85%
UPSC: 90%
clear cell ca: 84%

Question 2

5y OS for s.III g3 EAC and UPSC
Mayo data on pts, treated between 1999-2008

Answer 2

g3EAC: 49% (N-119)

UPSC: 40% (N-211)

~ age, LVSI, unresectable LN, regional XRT

Question 3

5y OS for s.IV g3 EAC and UPSC
Mayo data on pts, treated between 1999-2008

Answer 3

g3EAC: 9% vs. 12% for UPSC

~LVSI, T2, adjuvant chemo;
not ~ residual disease

Question 4

+ LN among g3EAC, UPSC, CCC
from Mayo data on pts, treated between 1999-2008 (median count 44)

Answer 4

Pelvic-PA LN:

g3EAC: 33-24%

UPSC: 35-30%

CCC: 21-10%

Question 5

GOG 249 population ?

Answer 5

High risk stage I-II patients: including serous 15% and clear cell 5% histology and high risk endometrioid cancers with HIR as per GOG-99

Question 6

GOG 249 results as per 2017 “press release”:

Answer 6

at median follow up of 53m:

82% had 3y RFS in both groups

90% 3y OS in both

Pelvic and PA recurrences at 5y: 9 % (20/25 in pelvis) for chBrachy vs 4% (6/12 pelvis) for XRT

No difference in cumulative incidence of vaginal and distant 🔄: 18% at 5y

Question 7

Adding Transtuzumab to CP for overexpressing Her-2/neu UPSC (30% of them) as per phase II GOG study p2018

Answer 7

overall median PFS: 8 vs 13m in experimental arm (HR 0.44, 90% CI)

9 vs. 17 m PFS among s.III-IV UPSC undergoing initial tx

Question 8

% of deaths from endometrial cancer attributed to type 2 cancers

Answer 8

75%

Per EAC SGO 2021 statement

Question 9

SLN false negative rate in type 2 EAC who had LND to renal vessels per Soliman?

Answer 9

4.3% false negative rate

89% mapped successfully

“those results further validated SLN algorithm” per 2021 SGO review